Release of TFPI by Anticoagulants in Cancer Patients by Standard or LMW Heparin
OBJECTIVES: I. Determine the patterns of tissue factor pathway inhibitor (TFPI) release
according to tumor type and type of anticoagulation (heparin or enoxaparin) in patients with
cancer. II. Determine the incidence of portacath clots and its correlation to TFPI
releasability in this patient population. III. Compare these anticoagulation drugs in terms
of releasability of TFPI in this patient population.
OUTLINE: This is a randomized study. Patients are stratified according to prior chemotherapy
within the past 3 weeks (yes vs no). Patients are randomized to one of two treatment arms.
Arm I: Patients receive a single dose of standard heparin subcutaneously (SQ) followed by
evaluation of tissue factor pathway inhibitor (TFPI) response at 5 and 10 minutes post
injection. Arm II: Patients receive a single dose of enoxaparin SQ followed by evaluation of
TFPI response as in arm I. Patients are followed monthly for 3 months.
PROJECTED ACCRUAL: A total of 20-200 patients will be accrued for this study over 6 months.
Observational Model: Cohort, Time Perspective: Prospective
Hau C. Kwaan, MD
Veterans Affairs Medical Center - Lakeside Chicago
United States: Federal Government
|Veterans Affairs Medical Center - Chicago (Lakeside)||Chicago, Illinois 60611|
|Evanston Northwestern Health Care||Evanston, Illinois 60201|